

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) Publication number:

0 593 868 A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 93112983.7

(51) Int. Cl.⁵: **C07K 15/26**, **C07K 3/08**,
A61K 47/48, **C08G 65/32**,
C07D 213/64, **C07C 69/96**

(22) Date of filing: 13.08.93

(30) Priority: 26.08.92 US 935770

(43) Date of publication of application:
27.04.94 Bulletin 94/17

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE**

(71) Applicant: **F. HOFFMANN-LA ROCHE AG**
Grenzacherstrasse 124
CH-4002 Basel(CH)

(72) Inventor: **Karasiewicz, Robert**
30 Deerfield Road
Parsippany, N.J. 07054(US)
Inventor: **Nalin, Carlo**
327 Forest Glenn Avenue
Franklin Lakes, N.J. 07417(US)
Inventor: **Rosen, Perry**
26 Sunset Drive
North Caldwell, N.J. 07006(US)

(74) Representative: **Mezger, Wolfgang, Dr. et al**
Grenzacherstrasse 124
Postfach 3255
CH-4002 Basel (CH)

(54) **PEG-interferon conjugates.**

(57) The present invention relates to physiologically active water soluble polyethylene glycol conjugates with interferon and to new polyethylene glycol compounds which can be used in the preparation of the conjugates.


EP 0 593 868 A1

Various natural and recombinant proteins have medical and pharmaceutical utility. Once they have been purified and formulated, they can be parenterally administered for various therapeutic indications. However, parenterally administered proteins may be immunogenic, may be relatively water insoluble, and may have a short pharmacological half life. Consequently, it can be difficult to achieve therapeutically useful blood levels of the proteins in patients.

These problems may be overcome by conjugating the proteins to polymers such as polyethylene glycol. Davis et al., U.S. Pat. No. 4,179,337, disclose conjugating polyethylene glycol (PEG) to proteins, such as enzymes and insulin, in order to result in conjugates where the protein would be less immunogenic but would retain a substantial proportion of its physiological activity. Nakagawa, et al. disclose conjugating PEG to islet-activating protein to reduce its side-effects and immunogenicity. Veronese et al., Applied Biochem. and Biotech, 11:141-152(1985), disclose activating polyethylene glycols with phenyl chloroformates to modify a ribonuclease and a superoxide dismutase. Katre et al., U.S., Pat. Nos. 4,766,106 and 4,917,888, also disclose solubilizing proteins by polymer conjugation. PEG and other polymers are conjugated with recombinant proteins to reduce their immunogenicity and increase their half-life. See Nitecki, et al., U.S. Pat. No. 4,902,502, Enzon, Inc., International Application No. PCT/US90/03133, Nishimura et al., European Patent Application 154,316 and Tomasi, International Application Number PCT/US85/02572.

Previous methods of forming PEG/protein conjugates and the conjugates which result from said methods present several problems. Among these problems is that certain methods of forming these protein-PEG conjugated may inactivate the protein so that the resulting conjugates may have poor biological activity. In addition, certain linkers utilized in forming these PEG-protein conjugates may be susceptible to *in vivo* hydrolytic cleavage. When such cleavage occurs after administration, these conjugates lose the beneficial properties provided by PEG.

One embodiment of the invention are novel interferon-PEG conjugates with unique linkers which connect an interferon (IFN) amino group to PEG. The present invention is directed in particular to physiologically active interferon conjugates having the general formula:



wherein R is lower alkyl; R¹, R², R³ and R⁴ are H or lower alkyl;

m is selected from integers ≥ 1 up to the number of accessible amino groups in the interferon;


W is O or NH;

x is an integer between 1 and 1000 and each of y and z is an integer from 0 to 1000, and the sum of x, y and z is 3 to 1000;

with the proviso that at least one of R¹, R², R³ and R⁴ is lower alkyl.

It is self-evident that the -NH-group in formula I is derived from an accessible amino group of the interferon molecule.

More specifically the two different interferon conjugates have the following formulae:



wherein R is lower alkyl; R¹, R², R³, R⁴ are H or lower alkyl; m is a number up to the number of accessible amino groups in the interferon and x, y and z are selected from any combination of numbers such that the conjugate has at least a portion of the biological activity of the protein which forms the conjugate; with the proviso that at least one of R¹, R², R³ and R⁴ is lower alkyl.


Brief Description of the Figures

Figure 1: Time course of PEG modification with the compound of Example 7. Interferon (5 mg/ml) was incubated with 10-fold, 20-fold, or 40-fold excess of reagent to protein for the times indicated in 25 mM Tricine (pH 10.0), 0.5 M KSCN, 100 mM NaCl. Aliquots were removed at various times, quenched with glycine and analyzed on a 15% SDS-PAGE gel. On the label "I" is for interferon.

Figure 2: Time course of PEG modification with the compound of Example 5. Interferon was incubated with a 3-fold or 10-fold excess of reagent for the indicated times as in Figure 1. At the times indicated, aliquots were removed, quenched with glycine, and analyzed on a 15% SDS-PAGE gel. "S" is the label for protein molecular weight standards, "I" is the label for interferon.

Figure 3: Comparison of PEG modification with the compound of Example 1 (left side), and of Example 3 (right side). Interferon was incubated with a 3-fold excess of each reagent for 0.25, 1.5 or 24 hours. Aliquots were removed, quenched with glycine and analyzed on a 15% SDS-PAGE gel. "S" is the label for protein molecular weight standards, "I" is the label for interferon.

In accordance with this invention, the IFN conjugates of formulae IA and IB can be produced by condensing activated PEG where a terminal hydroxy or amino group has been replaced by an activated linker. These reagents can then react with one or more of the amino groups in the IFN. Condensation with only one amino group to form a monoPEGylated conjugate is a preferred embodiment of this invention. Therefore, the invention also relates to novel activated compounds (reagents) which can be used to produce the interferon conjugates of the present invention. These compounds have the following general formulae:




wherein R is lower alkyl, R¹, R², R³, R⁴ and R⁵ are H or lower alkyl;

W is NH or O;



x is an integer between 1 and 1000 and each of y and z is an integer from 0 to 1000, and the sum of x, y and z is 3 to 1000,

provided that if W is NH or if W is O and R⁵ is H at least one of R¹, R², R³ and R⁴ is lower alkyl, and



wherein R is lower alkyl; R¹, R², R³ and R⁴ are H or methyl, x is an integer from 1 to 1000 and each of y and z is an integer from 0 to 1000, and the sum of x, y and z is 3 to 1000.

More specifically, formula II includes compounds of the following two types:



In IIA, IIB and III R, R¹, R², R³, R⁴, R⁵ are as above; and x, y, and z are selected from any combination of numbers such that the polymer when conjugated to a protein allows the protein to retain at least a portion of the activity level of its biological activity when not conjugated; with the proviso mentioned under formula II.

In accordance with this invention, by using the activated PEG reagents of formula IIA, IIB, or III to produce the conjugates, a linking bond between the free amino groups in a protein such as interferon (IFN) and the PEG is formed so that the resulting conjugate retains at least a portion of the biological activity of the protein with reduced immunogenicity. In addition, the linkage groups formed in the conjugate of this invention through the use of any one of the activated polyethylene glycols of formulae IIA, IIB, or III produces a protein conjugate which is not readily susceptible to *in vivo* hydrolytic cleavage and is not subject to the disadvantages present in PEG protein conjugates of the prior art.

In accordance with this invention, R, R¹, R², R³, R⁴, and R⁵ can be any lower alkyl, preferably methyl. The term lower alkyl designates lower alkyl groups containing from 1 through 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, etc. Generally the preferred alkyl group is a lower alkyl group containing from 1 to 4 carbon atoms with methyl being most preferable. R₁, R₂, R₃, R₄, and R₅ can also be hydrogen, but R¹, R², R³ and R₄ are not simultaneously hydrogen.

In accordance with this invention, x, y, and z can be selected from any combination of numbers such that the resulting conjugate contains at least a portion of the biological activity of the IFN which forms the conjugate. It is apparent that the sum of x, y, and z, and m is inversely proportional to the amount of biological activity of the IFN which is retained by the conjugate. The numerical value of x, y, and z represent the number of glycol units in the polyglycol which form the conjugate. The term m represents the number of free or accessible amino groups contained by the IFN which can react with the activated PEG mixture. The higher the value of m, and x, y, and z, the higher the molecular weight of the conjugate. In accordance with this invention x, y and z are any number so that molecular weight of the conjugate, excluding the weight of the protein, is between about 300 to about 30,000 daltons. Preferably for IFN, m is a number from 1 through 3. A highly preferred embodiment is a monoPEGylated conjugate where m is 1, produced by conditions such that a high yield is obtained of IFN conjugate composed of IFN where only one free amino group has reacted with the PEG reagent of formula II-A, or II-B, or III. In accordance with a preferred embodiment where m is 1, x, y, and z are any number so that the glycol which forms the conjugate has an average molecular weight of from about 300 to about 30,000 daltons, preferably about 1,000 to about 10,000 daltons, especially about 1,000 to about 5,000 daltons. In a particularly preferred embodiment, the molecular weight is about 2,000 daltons.

As far as the numbers x, y and z of the units are concerned, x is an integer from 1 to 1000 and each of y and z is an integer from 0 to 1000 and the sum of x, y and z is 3 to 1000.

In one preferred embodiment of the conjugates of formulae IA and IB, x and y are 5 to 500 and z is 0 to 100. In a particularly preferred embodiment, the glycol used is a mixture of glycols wherein x is between 10 to 100, y is between 1 to 10 and z is 0. Most preferred is an interferon conjugate of formula IA wherein m is 1, R, R² and R⁴ are CH₃; R¹ is H; x is about 19, y is about 2 and z is 0. This corresponds to an average molecular weight in the PEG unit of about 1000 daltons.

In order to avoid any doubts concerning the numbers of the units in the PEG molecule, characterization of the polyethylene glycol polymer by molecular weight is preferred over indicating the number of self repeating units (SRU) in the PEG polymer by x, y and z. These values may be difficult to assess due to potential inhomogeneity of the starting PEG compounds which are usually defined by their average molecular weight and not by the number of self-repeating units they contain. The starting PEG compounds of various molecular weights can be prepared by methods known in the art or can be obtained from commercial suppliers.

In case the values of x, y and z obtained by determination of the molecular weights or as indicated by the supplier are not integers (as will generally be the case), their values have to be rounded up or off in the usual way to allow an assignment of the integers to the polymeric molecule which probably forms the major part in the polymeric mixture.

When the reagent of any one of formula IIA, II-B, or III is reacted with an IFN, which contains more than one free amino group, the conjugate may be produced as a mixture of various reaction products of IFN with the PEG-reagent mixtures. These reaction products form as a result of the reaction of the PEG reagent with one or more of the free amino groups. This is sided by m in formula IA and IB. For example, where the IFN contains three free amino groups, the activated PEG reagent can react with one of the free amino groups, with two of the free amino groups or with all three. In this situation the mixture contains conjugated reaction products formed in all three cases. Since the various conjugated reaction products in this mixture have vastly different molecular weights, depending on the value of m, i.e. 1, 2, or 3, these reaction products can be separated by conventional methods such as chromatography. To determine if m, and x, y, and z have been selected properly, the separated conjugated reaction products can be screened for biological activity by the same means used to screen the parent IFN to determine if the conjugated reaction product still retains a portion of the biological activity of the IFN used to form the conjugate. In this manner, the numbers m and x, y, and z can be adjusted in any desired manner to provide the desired activity.

In accordance with the preferred embodiment, m is 1. Where m is 1, this conjugate can be obtained even when there are two or more free amino groups. The activated PEG reagent will react first with one of the free amino groups contained within the IFN. By regulating the concentration of the reagents such as the IFN and reaction conditions, in accordance with standard methods of amine condensation, one can regulate the degree of pegylation of the free amino groups contained within the protein. In proteins containing one or more free amino groups, where one of the free amino groups is more reactive than the other amino groups, conditions may be selected so that the protein is reacted with the activated PEG compound to form the compound of formula IA or IB where m is 1. Other free amino groups contained within amino acids which form the protein may be subsequently reacted with the PEG by allowing the condensation reaction to proceed longer or by utilizing other stronger conditions.


As used in the present specification and claims the terms interferon and IFN include all types of interferon (viz. molecules with an interferon activity), for example, α , β , γ and ω interferon, and all subtypes of these types, such as $\alpha 1$, $\alpha 2$, $\alpha 2A$, $\alpha 2B$ or $\alpha 2C$ and hybrids or chimeras of different types and/or subtypes. The interferon can be of whatever origin and may be obtained from natural sources, tissue
5 cultures or by recombinant DNA techniques. Methods for producing and isolating natural or recombinant interferons are well known in the art and are described, e.g. in patent applications Publ. Nos. EP 43 980, EP 211 148, EP 140 127, DE 3 028 919, USP 4 503 035 and USP 4 414 150.

The advantage of using the reagents of formulae IIA, IIB and III where at least one of R^1 , R^2 , R^3 , R^4 is lower alkyl, in particular methyl (alkyl substituted reagents) lies in an unexpected enhancement of the yield
10 of conjugate, i.e., PEGylated protein, when the alkyl substituted reagents are used as compared to corresponding unsubstituted reagents. Alkyl substituted reagents yield at least twice the amount of conjugates in the same amount of reaction time compared to the corresponding unsubstituted reagents in producing such conjugates.

If administered to patients for therapeutic purposes, the conjugates of formulae IA and IB produced
15 from the above-described substituted reagents would have an unexpectedly enhanced *in vivo* half-life in the bloodstream of the patient when compared to conjugate formed from corresponding unsubstituted reagents. Although *in vivo* half-life is directly proportional to the molecular weight of the conjugate, a conjugate produced from a substituted reagent, surprisingly will have as long a half-life as a higher molecular weight conjugate produced from unsubstituted reagent. A longer half-life for a therapeutic agent in a patient's
20 bloodstream provides enhanced efficiency for administering the agent to a patient. For example, conjugates made from alkyl substituted reagents can be administered less frequently and/or in lower amounts than conjugates made from the corresponding unsubstituted reagent. In order to enhance the efficiency of administration of biologically active protein conjugates with polyethylene glycol, increased molecular weights of polyethylene glycol have been used in forming these protein conjugates. However, biological
25 efficacy of the active conjugated IFN diminishes with increasing molecular weight. However, through the use of the conjugates of this invention produced with substituted reagents, efficiency of administration is enhanced over the use of the corresponding unsubstituted conjugate with less increase in molecular weight.

In another embodiment, the present invention also relates to processes for the preparation of the novel conjugates.


30 The conjugate of formula I-A can be produced as follows:



wherein R, R¹, R², R³, R⁴, and R⁵, m and x, y, and z are as above; with the proviso that any one or more of R¹, R², R³, R⁴ may be lower alkyl.

In this reaction a PEG-amine is mixed with the compound of formula IV in a hydrocarbon or chlorinated hydrocarbon solvent to produce the compound of formula IIA. The compound of formula IIA can be condensed in an aqueous medium with one or more of the free amino groups of the protein to produce the conjugate of formula IA. This reaction can be carried out under conventional conditions for condensing amines in an aqueous medium. Generally this reaction is carried out in a standard aqueous buffer solution having a pH of between 7 and 10 to produce the conjugate of formula IA. This reaction may produce a mixture of PEG protein conjugates of various molecular weights depending upon the number of free amino groups within the protein and the time of the reaction. The PEG protein conjugates may then be separated into their individual components by conventional methods such as high performance liquid chromatography (HPLC) or gel electrophoresis. Any conventional conditions for separating compounds by molecular weight with HPLC or gel electrophoresis may be used. Separation of this mixture can be carried out according to molecular weights of the products formed as described herein.

An IFN conjugate of formula IB can be prepared according to the following reaction scheme:




wherein R, R¹, R², R³, R⁴, R⁵, m, x, y, z and the proviso are as above.

The compound of formula IV is produced by condensing phosgene with 2-hydroxypyridine (substituted if R⁵ = lower alkyl) using any conventional method for condensing an acid halide with an alcohol.

The condensation of a PEG alcohol with the compound of formula IV is effected by using conventional conditions for condensing an alcohol with a carbonate to produce the compound of formula II-B. The

compound of formula II-B is condensed with the protein through one or more free amino groups on the protein to produce the compound of formula I-B. This reaction is carried out in the manner described for the condensation of the compound of formula IIA to produce the conjugate of formula I-A. Depending upon the number of free amino groups contained within the protein which react with the compound of formula II-B, the conjugate of formula I-B may be formed as a mixture of conjugates having different molecular weights. This conjugate mixture can be separated in the manner described hereinbefore.

The compound of formula IB can also be produced using the following reaction scheme:



wherein R, R¹, R², R³, R⁴, R⁵, m, x, and y are as above.

In this reaction scheme, PEG-alcohol is condensed with the compound of formula IV to produce the compound of formula III. In this reaction, the compound of IIB is formed as an intermediate which then reacts with a second mole of PEG-alcohol to produce the compound of formula III. In carrying out this reaction, the PEG-alcohol is present in at least 2 moles per mole of the compound of formula IV. In this procedure any conventional method of condensing an alcohol with a carbonate can be used. The compound

of formula III is reacted with interferon to form the conjugate of formula I-B in the manner described for the conversion of the compound of formula IIA to the compound of formula IA. Depending upon the amount of free amino groups contained by the protein, condensation of the compound of formula III with the protein produces a mixture of conjugates which can be separated into their individual components in the manner

hereinbefore described for the separation of the conjugate of formula IA.

In accordance with this invention, it has been found that the interferon-conjugates of this invention have the same utility as the protein used to form the conjugate. Therefore, these conjugates are therapeutically active in the same manner as the protein from which they are formed and can be used in the same manner as the protein itself without producing the undesired immune responses which may be connected with the administration to subjects of the proteins themselves. Therefore, the present invention also comprises the pharmaceutical compositions on the basis of the compounds of formula I or their salts and to methods for producing them.

The pharmaceutical compositions of the present invention used in the control or prevention of illnesses comprises an interferon conjugate of the general formula I and a therapeutically inert, non toxic and therapeutically acceptable carrier material. The pharmaceutical compositions to be used can be formulated and dosed in a fashion consistent with good medical practice taking into consideration the disorder to be treated, the condition of the individual patient, the site of delivery of the protein conjugate, the method of administration and other factors known to practitioners.

The following examples represent illustrative embodiments of the present invention without limiting it by them.

As used in these examples, Jeffamine M-2070 is a 2070 average molecular weight monomethoxypolyoxyalkylene propylamine polymer derived from propylene and ethylene oxide which is composed of a polyethylene glycol backbone and contains an average of 30% randomly incorporated propylene oxide groups.

Jeffamine M-1000 is a 1000 average molecular weight monomethoxypolyalkylene propylamine polymer derived from propylene and ethylene oxide which is composed of a polyethylene glycol backbone containing 14% of specifically incorporated propylene oxide groups where x is an average of 18.6, y is an average of 1.6, and z is 0 (x, y and z are used here with the same significance as described above).

All reagents described in these examples may be stored dessicated in amber glass at 4°C until needed. Fresh aliquots are used for each modification.

Examples

Example 1

Preparation of alpha, alpha-Oxomethylene bis[omega-methoxypoly(oxy-1,2-ethanediyl)] SRU 111

From a suspension of 1.5 g MPEG (methoxypolyethylene glycol) (m.w. -5000) in 80 ml of dry toluene was distilled 50 ml of solvent. The solution was then cooled and 30.5 mg of di-2-pyridylcarbonate added. The resulting mixture was then refluxed for 24 hr. The solution was then cooled and the resulting precipitate filtered and washed with a small volume of toluene followed by diethyl ether. The solid was then dried under high vacuum to give 0.6 g of alpha, alpha'-oxomethylene bis(omega-methoxypoly(oxy-1,2-ethanediyl)) SRU 111 as a white powder. PEG-modified interferon was prepared by method 1 described below.

Preparation of PEG-modified Interferon-alpha.

Method 1: Recombinant interferon-alpha at 5 mg protein per ml was dialyzed against a buffer containing 5 mM sodium acetate, pH 5.0, 120 mM NaCl. Potassium thiocyanate was added to obtain a final concentration of 0.5 M, and the pH adjusted by addition of one-tenth volume of 1 M Tricinesodium hydroxide, pH 11.9, to obtain a final pH 10.0 solution. PEG-reagent was added to the protein at a 3:1 molar ratio from solid or dissolved in DMSO (the volume of DMSO was less than 10% of the total). Modification was allowed to proceed at room temperature for a time from 30 minutes to 4 hours, followed by addition of 1 M L-glycine (pH 6.3) to a final concentration of 20 mM to stop further modification. PEG-modified protein was precipitated by addition of 3.5 M ammonium sulfate, 50 mM sodium phosphate, pH 7.0, to a final concentration of 1.1 M ammonium sulfate (1.0 M ammonium sulfate for a PEG-10000), the precipitate collected by centrifugation, washed and redissolved in 25 mM ammonium acetate, pH 5.0. PEG-modified proteins were purified by chromatography on a hydrophobic exchange column (for example 75 x 7.5 mm) such as BioRad TSK Phenyl-5-PW or Toyopearl Phenyl-650M, using a gradient of

decreasing ammonium sulfate in 50 mM sodium phosphate, pH 7.0. Alternatively, PEG-IFN was purified by gel filtration on a Sephacryl S-200 column (for example a 90 cm. x 3.2 cm. column) (Pharmacia) that was equilibrated in 25 mM sodium acetate (pH 5.0), 200 mM NaCl. PEG-modified protein was identified by SDS-PAGE. Protein eluted from the column corresponding to interferon having one (PEG₁-IFN) or two (PEG₂-IFN) bound PEG were pooled, concentrated and protein determined by absorbance at 280 nm or by colorimetric assay (Pierce). PEG-IFN was stored at 4°C in buffer containing 50 mM sodium phosphate, pH 7.0, 0.3 M ammonium sulfate.

Method 2: Interferon α -2a at a protein concentration of approximately 6 mg per mL, was dialyzed into 5 mM sodium acetate, pH 5.0, 0.12 M sodium chloride. The protein concentration was determined by measuring the absorbance at 280 nm using 1.0 mg⁻¹mL as the extinction coefficient. The protein solution was mixed with the modifying reagent at a 1:3 molar ratio of protein to reagent. The modification reaction was initiated by adjusting the pH to 10.0 using one-tenth volume of 0.1 M Na₂B₄O₇-NaOH, pH 10.7. Following incubation at room temperature for one hour, the reaction was stopped by addition of one-twentieth volume of 1 M glycine, pH 7.5. After 3-5 minutes, the pH was decreased to 5.0-6.0 by addition of one-twentieth volume of 1 M sodium acetate, pH 4.0.

The solution containing PEG-interferon, quenched reagent and unmodified interferon was diluted four-fold with 40 mM ammonium acetate, pH 4.5, and loaded onto a CM-cellulose column (Whatman CM-52, approximately 0.5 ml resin per mg protein). After washing the column by 5 volumes of 40 mM ammonium acetate, pH 4.5, PEG-interferon and unmodified interferon were eluted using a linear sodium chloride gradient (0 - 0.5 M) in the 40 mM ammonium acetate pH 4.5. Fractions containing protein were identified by absorbance at 280 nm, and PEG-interferon containing fractions were identified by SDS-PAGE.

PEG-interferon was further purified by size exclusion-gel filtration chromatography on a column containing Sephacryl S-200 resin (Pharmacia LKB). Fractions eluted from the column were analyzed by SDS-PAGE and the peak material containing PEG-interferon pooled.

Example 2

Preparation of alpha, alpha-Oxomethylene bis[omega-methoxypoly(oxy-1,2-ethanediyl)]SRU 28.3

By the procedure described in Example 1, MPEG (m.w. 1300) was converted to alpha, alpha-oxomethylene bis[omega-methoxypoly(oxy-1,2-ethanediyl)] SRU 28.3, and PEG-modified interferon was prepared using this reagent by method 1 described in Example 1.

Example 3

Preparation of alpha-Methyl-omega-[2[(2-Pyridinyloxy)carbonyl]oxy]-ethoxy]-poly-(oxy-1,2-ethanediyl) SRU 111.7

From a solution of 1 g MPEG molecular weight 5000 dissolved in 30 ml of dry CH₂Cl₂ was distilled 10 ml of solvent. The solution was cooled to room temperature and 132 mg (0.6 mM) of di-2-pyridyl carbonate and 4 mg of DMAP were added. The resulting solution was then stirred for 14 hours and the solvent removed under vacuum. The residue was triturated with diethyl ether and the resulting precipitate filtered. The product was then dissolved in 7 ml of dry glyme, warmed to cause dissolution, and the resulting solution allowed to cool and stand at room temperature for several hours. The resulting precipitate was then filtered and washed with 2x5 ml of dry glyme. The solid was then dried in a vacuum oven and under a stream of nitrogen to give 0.7 g of alpha-[(2-pyridinyloxy)carbonyl]omega-methoxypoly(oxy-1,2-ethanediyl) SRU 111.7.

Anal. Calcd for C₉H₁₁NO₄(CH₂CH₂O)_{111.7}: C, 54.57; H, 9.02; N, 0.28. Found: C, 54.51; H, 9.19; N, 0.28.

PEG-modified interferon was prepared using this reagent by method 1 described in Example 1.

Example 4

Preparation of alpha-(2-Pyridinyloxy)carbonyl]omega-methoxypoly(oxy-1,2-ethanediyl) SRU 225

By the procedure described in Example 3, MPEG molecular weight 10,000 was converted to alpha-[(2-pyridinyloxy)carbonyl]omega-methoxypoly(oxy-1,2-ethanediyl), SRU 225.


Anal. Calcd for C₉H₁₁NO₄(CH₂CH₂O)₂₂₅: C, 54.54; H, 9.08; N, 0.14. Found: C, 54.54; H, 9.12; N, 0.11.

PEG-modified interferon was prepared using this reagent by method 1 described in Example 1.

Example 5Preparation of alpha-Methyl-omega-[2-[2-[(2-pyridinyloxy) carbonyl]oxy]-propoxy]propoxy]poly(oxy-1,2-ethanediyl) SRU 64.7

From a solution of 0.5 g of alpha-2-[2-(hydroxypropoxy)propyl]-omega-methoxypoly(oxy-1,2-ethanediyl) SRU 64.7 in 40 ml of dry CH_2Cl_2 was distilled 15 ml of solvent. To the solution was then added 108 mg of di-2-pyridyl carbonate, 4 mg of DMAP and several beads of 4A molecular sieve. The mixture was then stirred overnight, filtered and the solvent was then removed under reduced pressure. The residue was purified by means of size exclusion chromatography.

This reagent corresponds to a compound with the formula



wherein n is about 64.

This corresponds to a molecular weight in the polymer of about 3000 daltons.

PEG-modified interferon was prepared using this reagent by method 1 described in Example 1.

Example 6Preparation of alpha-Methyl-omega-[2-[2-[(2-pyridinyloxy)carbonyl]oxy]-propoxy]propoxy]poly(oxy-1,2-ethanediyl) SRU 110

By the procedure described in Example 5, alpha-2-[2-(hydroxy-propoxy)propyl]-omega-methoxypoly(oxy-1,2-ethanediyl) SRU 110, was converted to alpha-methyl-omega-[2-[2-[(2-pyridinyloxy)carbonyl]oxy]-propoxy]propoxy]poly(oxy-1,2-ethanediyl) SRU 110.


This reagent (IIB-2) corresponds to the one described in Example 5 (IIB-1) except that n is about 110 which corresponds to about 5000 daltons.

PEG-modified interferon was prepared using this reagent by method 1 described in Example 1.

Example 7Preparation of Methyloxirane, polymer with oxirane, [2-[(2-pyridinyloxy)-carbonyl]amino]propyl methyl ether (MO/O = 10/32)

From a solution of 1 g of Jeffamine M-2070 (Texaco Chemical Co.) in 40 ml of dry CH_2Cl_2 was distilled 15 ml of solvent. The solution was cooled to 0°C and 215 mg of di-2-pyridyl carbonate was added. The resulting solution was stirred for an additional 4 hr at 0°C after which time the solvent was removed under reduced pressure. The residue was then purified by means of two phenomenex size exclusion columns attached in sequence (500Å and 1000 Å). The product shows two bands in the UV at 232 nm and 310 nm.

This reagent corresponds to a compound with the formula



wherein R⁵ is H, R² is H or methyl, and, as an average distribution, n is 32 if R² is H and n is 10 if R² is methyl.

PEG-modified interferon was prepared using this reagent by method 2 described in Example 1.

5 Example 8

Preparation of Methyloxirane, polymer with oxirane, [2-[(3-methyl-2-pyridinyloxy)carbonyl]amino]-propyl methyl ether (MO/O = 10/32)

10 By the procedure described in Example 7, 1 g of Jeffamine M-2070 was reacted with bis(3-methyl-2-pyridyl)carbonate to give methyloxirane, polymer with oxirane, [2-[(3-methyl-2-pyridinyloxy) carbonyl]-amino]propyl methyl ether (MO/O = 10/32).

This reagent (IIA-2) corresponds to the one described in Example 7 (IIA-1) except that R⁵ is CH₃.

PEG-modified interferon was prepared using this reagent by method 1 described in Example 1.

15

Example 9


Preparation of Methyloxirane, polymer with oxirane, [2-[(2-pyridinyloxy)-carbonyl]amino]propyl methyl ether, block (MO/O = 1.6/18.6)

20

By the procedure described in Example 7, 0.6 g of Jeffamine M-1000 (Texaco Chemical Co.) was reacted with 155.6 mg of di-2-pyridyl carbonate to give methyloxirane, polymer with oxirane, [2-[(2-pyridinyloxy)carbonyl]-amino]propyl methyl ether, block (MO/O = 1.6/18.6).

This yields a compound with the formula

25



35 having the indicated average distribution of the units in the polymeric product.

PEG-modified interferon was prepared using this reagent by method 1 described in Example 1.

40 **Antiviral activity of interferon:** Antiviral activity of interferon and PEG-modified interferon was determined (Rubenstein, et al., (1981) J. Virol. 37:755-758; Familletti, et al., (1981) Methods Enzymol. 78:387-394). All assays were standardized relative to control. The interferon standard used in the assay had specific activity of 2×10^8 units per mg of protein.

Conditions used for modification of interferon were based on optimized protocols as described. PEG-modification was analyzed by SDS-PAGE for conversion of interferon to monoPEG-interferon over various times of incubation (chemical reactivity), and for distribution into different species of PEG-interferon conjugates (site selectivity). In SDS-PAGE, PEG-modified species were observed as slower migrating bands on the gel. Both monoPEG and diPEG-interferons were produced in sufficient yield so that these species could be purified from the reaction mixtures by hydrophobic interaction chromatography. Purified PEG-interferons were tested for antiviral activity and compared with unmodified interferon-a2a standards. The molecular weights of the polymers used as well as the antiviral activity of some of the pegylated derivatives are described in Table 1.

50


55

Table 1

Physical Properties of PEG Reagents and Biological Activities of their Protein Conjugates			
Compound of Example:	Polymer Mol/Wt	Antiviral Activity (% control)	
		monoPEG	diPEG
4	10000	25	2
3	5000	40	4
1	5000	40	ND
6	5000	40	ND
5	3000	60	ND
7	2070	45	ND
2	1300	70	ND
9	1000	100	40
ND = not determined			

Claims

1. An interferon conjugate of the formula:



wherein R is lower alkyl; R¹, R², R³ and R⁴ are H or lower alkyl;

m is selected from integers ≥ 1 up to the number of accessible amino groups in the interferon;

W is O or NH;


x is an integer between 1 and 1000 and each of y and z is an integer from 0 to 1000, and the sum of x, y and z is 3 to 1000;

with the proviso that at least one of R¹, R², R³ and R⁴ is lower alkyl.

2. An interferon conjugate of claim 1 wherein x, y and z are selected such that the molecular weight of the polymeric unit in the conjugate is in the range of about 300 daltons to about 30000 daltons.
3. An interferon conjugate of claim 1 wherein m is 1.
4. An interferon conjugate of claim 1 wherein R is methyl.
5. An interferon conjugate of claim 2 wherein x, y and z are selected such that the molecular weight of the polymeric unit in the conjugate is in the range of about 1000 daltons to about 5000 daltons.
6. An interferon conjugate of claim 2 wherein x, y and z are selected such that the molecular weight of the polymeric unit in the conjugate is in the range of about 1000-2200 daltons.
7. An interferon conjugate of claim 1 wherein x and y are 5.0 to 500.0 and z is 0.0 to 4.0.
8. An interferon conjugate of claim 1 wherein x is 10.0 to 100.0, y is 1.0 to 10.0 and z is 0.
9. An interferon conjugate of claim 1 wherein the interferon is interferon $\alpha 2A$.

10. The interferon conjugate of claim 9 wherein W is NH; m is 1; R, R² and R⁴ are CH₃; R¹ is H; x is 18.6, y is 1.6 and z is 0.

11. A compound of formula:



wherein R is lower alkyl, R¹, R², R³, R⁴ and R⁵ are H or lower alkyl;

W is NH or O;

x is an integer between 1 and 1000 and each of y and z is an integer from 0 to 1000, and the sum of x, y and z is 3 to 1000,


provided that if W is NH or if W is O and R⁵ is H at least one of R¹, R², R³ and R⁴ is lower alkyl.

12. A compound of claim 11 wherein x, y and z are selected such that the molecular weight of said compound is in the range of about 300 daltons to about 30000 daltons.

13. A compound of claim 11 wherein R is methyl.

14. A compound of claim 13 wherein x is 10.0 to 100.0, y is 1.0 to 10.0 and z is 0.0 to 4.0.

15. A compound of the formula:



wherein R is lower alkyl; R¹, R², R³ and R⁴ are H or methyl, x is an integer from 1 to 1000 and each of y and z is an integer from 0 to 1000, and the sum of x, y and z is 3 to 1000.

16. A compound of claim 15 wherein x, y and z are selected such that the molecular weight of said compound is in the range of about 300 daltons to about 30000 daltons.

17. A compound of claim 15 wherein at least one of R¹, R², R³ and R⁴ is lower alkyl.

18. A compound of claim 15 wherein R is methyl.

19. Interferon conjugates in accordance with any one of claims 1-10 for use as therapeutically active compounds in the treatment or prophylaxis of illnesses.

20. Process for the preparation of an interferon conjugate as claimed in any one of claims 1-10, which process comprises reacting a compound claimed in claims 11-18 with interferon or a salt thereof and isolating the interferon conjugate from the reaction mixture.

21. Pharmaceutical compositions comprising an interferon conjugate as claimed in any one of claims 1-10 and a therapeutically inert carrier.

EP 0 593 868 A1

22. Pharmaceutical compositions for the treatment or prophylaxis of immunomodulatory disorders such as neoplastic diseases or infectious diseases comprising an interferon conjugate as claimed in any one of claims 1-10 and a therapeutically inert carrier.

5 **23.** The use of the interferon conjugates according to any one of claims 1-10 in the treatment or prophylaxis of illnesses of others than human beings.

24. The use of interferon conjugates according to any one of claims 1-10 for the manufacture of medicaments for use in the treatment or prophylaxis of illnesses.

10

15

20

25

30

35

40

45

50

55

FIGURE 1




FIGURE 2





FIGURE 3





European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

which under Rule 45 of the European Patent Convention
shall be considered, for the purposes of subsequent
proceedings, as the European search report

Application Number

EP 93 11 2983

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 5)
D,Y	EP-A-0 154 316 (TAKEDA CHEMICAL INDUSTRIES LTD.) 11 September 1985 * pages 1-22; claims 1 and 5 * ---	1-24	C07K15/26 C07K3/08 A61K47/48 C08G65/32 C07D213/64 C07C69/96
Y	EP-A-0 426 488 (JAPAN CHEMICAL RESEARCH CO., LTD.) 8 May 1991 * page 4, lines 26-32 * ---	1-24	
P,Y	EP-A-0 510 356 (HOFFMANN-LA ROCHE AG) 28 October 1992 * claims 14 and 15; claim 17 * ---	1-24	
Y	WO-A-8 700 056 (CETUS CORPORATION) 15 January 1987 * Claims; description pages 1-6; page 4, lines 24-26 * ---	1-24	
A	EP-A-0 400 472 (SUMIMOTO) 5 December 1990 * claims * -----	15, 16	
			TECHNICAL FIELDS SEARCHED (Int. Cl. 5)
			C07K A61K C08G C07D C07C

INCOMPLETE SEARCH

The Search Division considers that the present European patent application does not comply with
the provisions of the European Patent Convention to such an extent that it is not possible to carry
out a meaningful search into the state of the art on the basis of some of the claims

Claims searched completely:

Claims searched incompletely:

Claims not searched:

Reason for the limitation of the search:

see sheet C

Place of search

MUNICH

Date of completion of the search

23 FEBRUARY 1994

Examiner

HERMANN R.

CATEGORY OF CITED DOCUMENTS

- A : particularly relevant if taken alone
- Y : particularly relevant if combined with another
document of the same category
- A : technological background
- () : non-written disclosure
- P : intermediate document

T : theory or principle underlying the invention

E : earlier patent document, but published on, or
after the filing date

D : document cited in the application

L : document cited for other reasons

& : member of the same patent family, corresponding
document



European Patent
Office

CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- ☐ All claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for all claims.
- ☐ Only part of the claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid.
- namely claims:
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirement of unity of invention and relates to several inventions or groups of inventions.

namely:

see sheet -B-

- ☒ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid.
- namely claims:
- ☐ None of the further search fees has been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims.
- namely claims:



European Patent
Office

EP 93 11 2983 -B

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirement of unity of invention and relates to several inventions or groups of inventions, namely:

1. Claims 1-14, 17-22, 24 (completely),
15, 16 (partially):

Compounds of claim 1, intermediates, processes, compositions

2. Claims 15, 16 (partially):

Intermediates not leading to the final products of claim 1 (R_1 - R_4 all being hydrogen)



EP 93 11 2983

-C-

INCOMPLETE SEARCH

Claim not searched: 23

Method for treatment of the human or
animal body by surgery or therapy
(see article 52(4) of the European
Patent Convention)

THIS PAGE BLANK (USPTO)

FIGURE 1




FIGURE 2

THIS PAGE BLANK (USPTO)





FIGURE 3



THIS PAGE BLANK (USPTO)